{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:54:52Z","timestamp":1781531692016,"version":"3.54.5"},"reference-count":13,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1136\/dtb.2024.255358rep","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T13:25:16Z","timestamp":1729776316000},"page":"109-111","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Two cases of linagliptin-associated bullous pemphigoid resulting in sepsis and endocarditis"],"prefix":"10.1136","volume":"63","author":[{"given":"Michael","family":"Vanner","sequence":"first","affiliation":[{"name":"Medicine, University Hospitals Sussex NHS Foundation Trust, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Tanner","sequence":"additional","affiliation":[{"name":"University Hospitals Sussex NHS Foundation Trust, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Chakera","sequence":"additional","affiliation":[{"name":"Royal Sussex County Hospital, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"2025082700540555000_63.7.109.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2013.01.006"},{"key":"2025082700540555000_63.7.109.2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous pemphigoid","volume":"94","author":"Miyamoto","year":"2019","journal-title":"An Bras Dermatol"},{"key":"2025082700540555000_63.7.109.3","article-title":"Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus","volume":"2008","author":"Richter","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082700540555000_63.7.109.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69705-5"},{"key":"2025082700540555000_63.7.109.5","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0210"},{"key":"2025082700540555000_63.7.109.6","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13790","article-title":"Dipeptidyl\u2010Peptidase IV inhibitors (Dpp4I)\u2010Associated Bullous Pemphigoid: estimating the clinical profile and exploring Intraclass differences","volume":"33","author":"Kridin","year":"2020","journal-title":"Dermatol Ther"},{"key":"2025082700540555000_63.7.109.7","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case control study from France and Switzerland","volume":"78","author":"Benzaquen","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2025082700540555000_63.7.109.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-021-03192-8","article-title":"Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin","volume":"19","author":"Chouchane","year":"2021","journal-title":"J Transl Med"},{"key":"2025082700540555000_63.7.109.9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/07853890.2018.1443346","article-title":"Relapse of bullous pemphigoid: an update on this stubborn clinical problem","volume":"50","author":"Wang","year":"2018","journal-title":"Ann Med"},{"key":"2025082700540555000_63.7.109.10","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/bjd.19611","article-title":"International validation of the bullous pemphigoid disease area index severity score and calculation of cut\u2010off values for defining mild, moderate and severe types of bullous pemphigoid","volume":"184","author":"Masmoudi","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025082700540555000_63.7.109.11","unstructured":"The use of the WHO-UMC system for standardised case causality assessment, Available: https:\/\/www.who.int\/docs\/default-source\/medicines\/pharmacovigilance\/whocausality-assessment.pdf [Accessed 23 Sep 2023]."},{"key":"2025082700540555000_63.7.109.12","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0287"},{"key":"2025082700540555000_63.7.109.13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/00365540500277367","article-title":"Does steroid exposure adversely affect the outcome of subacute bacterial endocarditis? Report of two cases","volume":"38","author":"Ahmad","year":"2006","journal-title":"Scand J Infect Dis"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2024.255358rep","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:54:16Z","timestamp":1756281256000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2024.255358rep"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":13,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,6,30]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/dtb.2024.255358rep"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2024.255358rep","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"value":"0012-6543","type":"print"},{"value":"1755-5248","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]}}}